Definium Therapeutics (DE:MMQ0)

FRANKFURT:MMQ0

MMQ0

Definium Therapeutics

RESEARCH TOOLSreports

Want to see DE:MMQ0 full AI Analyst Report?

Definium Therapeutics (MMQ0) Price & Analysis

12 Followers

MMQ0 Stock Chart & Stats

€18.85

-€0.45(-5.84%)

At close: Jan 08 4:00 PM EST

€18.85

-€0.45(-5.84%)

Day’s Range― - ―

52-Week Range€4.73 - €19.00

Previous CloseN/A

VolumeN/A

Average Volume (3M)296.00

Market Cap

€1.87B

Enterprise Value€2.00B

Total Cash (Recent Filing)€411.59M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta1.04

Next Earnings

May 07, 2026

EPS Estimate

-0.41

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.43

Shares Outstanding99,698,130

10 Day Avg. Volume102

30 Day Avg. Volume296

Financial Highlights & Ratios

PEG Ratio-0.19

Price to Book (P/B)3.60

Price to Sales (P/S)0.00

P/FCF Ratio-9.09

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€32.79

Price Target Upside73.98% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering13

EPS Forecast (FY)-1.66

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial ReadoutsTopline results from late-stage Phase III trials of DT120 in generalized anxiety disorder and major depressive disorder will directly influence the company's regulatory trajectory and valuation potential.

Market Opportunity And PrevalenceIncreasing diagnosed prevalence of generalized anxiety disorder and a large untreated patient population create a significant commercial opportunity for DT120 if approved and successfully reimbursed.

Safety Profile And KOL SupportA relatively benign safety profile for DT120 combined with favorable feedback from key opinion leaders could reduce adoption barriers and support clinician confidence if efficacy is confirmed.

Bears Say

Financing And Cash RunwayHigh cash burn to support multiple late-stage trials raises financing risk and could necessitate capital raises that dilute existing shareholders before commercialization generates revenue.

Regulatory And Controlled Substance RiskDT120's relation to a tightly controlled substance introduces additional regulatory scrutiny and potential approval challenges that could complicate development and market access.

Treatment Delivery ConstraintsLengthy in-clinic treatment sessions required for DT120 could restrict patient throughput at clinics and limit broad commercial adoption despite positive clinical data.

Definium Therapeutics News

Trump Trade: President to sign order on psychedelic used for PTSD

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by...

2d ago

PBM

SPY

Definium Therapeutics initiated with a Buy at Stifel

Stifel analyst Paul Matteis initiated coverage of Definium Therapeutics (DFTX) with a Buy rating and $30 price target...

3d ago

DFTX

Trump to sign order on psychedelic used for PTSD, CBS News says

A psychedelic used in some countries to treat post-traumatic stress disorder is expected to get a closer examination...

3d ago

PBM

ATAI

Psychedelic: Clearmind’s CMND-100 meets primary endpoint in trial

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on...

3d ago

BMY

CMND

Definium Therapeutics price target raised to $38 from $25 at Canaccord

Canaccord analyst Sumant Kulkarni raised the firm’s price target on Definium Therapeutics (DFTX) to $38 from $25 and...

3d ago

DFTX

Definium Therapeutics initiated with an Overweight at Piper Sandler

Piper Sandler initiated coverage of Definium Therapeutics (DFTX) with an Overweight rating and $49 price target The firm...

9d ago

DFTX

Psychedelic: Clearmind completes treatment, follow-up for CMND-100 trial

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on...

17d ago

ATAI

CMND

Definium Therapeutics announces publication of study on general anxiety disorder

Definium Therapeutics (DFTX) announced results from a retrospective, longitudinal study published in the Journal of Mood and Anxiety...

19d ago

DFTX

Definium Therapeutics (DFTX): Reinforced Buy on Upcoming DT120 Data Catalysts and Commercialization Roadmap

Needham analyst Ami Fadia has maintained their bullish stance on DFTX stock, giving a Buy rating yesterday. Ami...

3d ago

DFTX

Mind Medicine Readies for Data-Rich 2026 Pivot

Mind Medicine Inc. (($DFTX)) has held its Q4 earnings call. Read on for the main highlights of the...

1M ago

DFTX

Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on...

2M ago

PBM

ATAI

Definium Therapeutics price target raised to $40 from $18 at Maxim

Maxim analyst Michael Okunewitch raised the firm’s price target on Definium Therapeutics (DFTX) to $40 from $18 and...

2M ago

DFTX

Definium Therapeutics: Late-Stage Pipeline Progress and Upcoming Phase 3 Readouts Support Buy Rating and Favorable Risk-Reward

Definium Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ami Fadia from...

2M ago

DFTX

Definium Therapeutics Issues Inducement Stock Options to New Hires

Definium Therapeutics ( ($DFTX) ) has provided an announcement. Definium Therapeutics has granted stock options to two newly...

2M ago

DFTX

MMQ0 FAQ

What was Definium Therapeutics’s price range in the past 12 months?

Definium Therapeutics lowest stock price was €4.73 and its highest was €19.00 in the past 12 months.

What is Definium Therapeutics’s market cap?

Definium Therapeutics’s market cap is €1.87B.

When is Definium Therapeutics’s upcoming earnings report date?

Definium Therapeutics’s upcoming earnings report date is May 07, 2026 which is in 18 days.

How were Definium Therapeutics’s earnings last quarter?

Definium Therapeutics released its earnings results on Feb 26, 2026. The company reported -€0.433 earnings per share for the quarter, missing the consensus estimate of -€0.411 by -€0.022.

Is Definium Therapeutics overvalued?

According to Wall Street analysts Definium Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Definium Therapeutics pay dividends?

Definium Therapeutics does not currently pay dividends.

What is Definium Therapeutics’s EPS estimate?

Definium Therapeutics’s EPS estimate is -0.41.

How many shares outstanding does Definium Therapeutics have?

Definium Therapeutics has 99,698,130 shares outstanding.

What happened to Definium Therapeutics’s price movement after its last earnings report?

Definium Therapeutics reported an EPS of -€0.433 in its last earnings report, missing expectations of -€0.411. Following the earnings report the stock price went up 2.817%.

Which hedge fund is a major shareholder of Definium Therapeutics?

Currently, no hedge funds are holding shares in DE:MMQ0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Definium Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-84.39%

Trailing 12-Months

Asset Growth

45.66%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Definium Therapeutics

Definium Therapeutics, Inc. is a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Definium Therapeutics (MMQ0) Earnings & Revenues

Historic Earnings Reports

MMQ0 Earnings Call

Q4 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call emphasized clear operational and clinical progress: multiple pivotal trials on track with strong enrollment, a favorable blinded SSRE in Voyage that suggests high statistical power, supportive Phase II efficacy data (published in JAMA), an expanded commercial and leadership team, and a strengthened balance sheet with cash runway into 2028. These positives are tempered by substantial y/y expense increases and a larger net loss, dependence on upcoming pivotal results and regulatory interactions, and the absence of disclosed long-term open-label durability data to date. Overall, the company appears well-capitalized and operationally prepared entering a data-rich 2026, but material clinical and regulatory outcomes remain pending.View all DE:MMQ0 earnings summaries

MMQ0 Stock 12 Month Forecast

Average Price Target

€32.79

▲(73.98% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"€4","18":"€18","32":"€32","46":"€46","60":"€60"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":59.4418748,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€59.44</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.7949314968,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€32.79</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.229241,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€21.23</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,18,32,46,60],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.65,19.018605753846153,22.387211507692307,25.75581726153846,29.124423015384615,32.49302876923077,35.86163452307692,39.23024027692308,42.59884603076923,45.967451784615385,49.33605753846154,52.70466329230769,56.07326904615385,{"y":59.4418748,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.65,16.968840884369232,18.287681768738462,19.606522653107692,20.925363537476922,22.244204421846153,23.563045306215383,24.881886190584616,26.200727074953846,27.519567959323076,28.838408843692307,30.157249728061537,31.476090612430767,{"y":32.7949314968,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.65,16.079172384615386,16.50834476923077,16.937517153846155,17.36668953846154,17.795861923076924,18.225034307692308,18.654206692307692,19.083379076923077,19.51255146153846,19.941723846153845,20.37089623076923,20.800068615384614,{"y":21.229241,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.38,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.47,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.6,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.18,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.8,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.09,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.04,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.53,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.25,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.88,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.6,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.65,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >